ClinicalTrials.gg
CompletedNCT05687916Updated Jan 9, 2025Results posted

A Study of TAK-861 in Participants With Narcolepsy Type 2

A Phase 2 interventional study of Placebo and TAK-861 2 mg in Narcolepsy Type 2, sponsored by Takeda. Completed at 56 sites in 12 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.

Enrollment
9th of 12
71 · median 95
Started
2023
with 2 others
Phase 2
6 of 16
2 open now
Registered
7th of 16
by date

Among the 16 studies in Narcolepsy by Takeda, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 7th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Narcolepsy by Takeda, or all of them as a file.
02

Study summary

The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT).

The study will enroll approximately 60 participants and they will be randomly assigned to 3 groups (20 per group) to take one of two different doses of TAK-861 or a placebo. All the participants will receive the treatment for 8 weeks. Participants will be asked to complete some questionnaires during the study. This trial will be conducted in North America, Europe, and Asia Pacific.

Read the detailed description

The drug being tested in this study is called TAK-861. TAK-861 is being tested to treat people who have narcolepsy without cataplexy [Narcolepsy Type 2 (NT2)]. This study will evaluate the efficacy, safety, and tolerability of 2 oral doses of TAK-861.

The study will enroll approximately 60 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • TAK-861 Dose 1
  • TAK-861 Dose 2
  • Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

This is a multi-center trial to be conducted worldwide. The overall time to participate in this study is approximately 18 weeks.

03

Conditions studied

  • Narcolepsy Type 2

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is aged 18 to 70 years, inclusive, at the time of signing the form (ICF).

Note: In Japan, participants aged 16 to 70 years, inclusive, may be included.

  • The participant has an International Classification of Sleep Disorders, 3rd edition (ICSD-3) diagnosis of NT2 by preceding polysomnography (PSG)/ multiple sleep latency test (MSLT), performed within the past 5 years.

Note: If there is a potential participant with NT2 for whom a diagnostic nocturnal polysomnography (nPSG)/MSLT was performed more than 5 years ago or is not available, the site may repeat the diagnostic PSG/MSLT.

Exclusion criteria

Exclusion Criteria:

  • The participant has a current medical disorder, other than narcolepsy without cataplexy, associated with EDS.
  • The participant has history of epilepsy, seizure, or convulsion, or has a family history of inherited disorders associated with seizure (except for a single febrile seizure in childhood).
  • The participant has one or more of the following psychiatric disorders:

    1. Any current unstable psychiatric disorder.
    2. Current or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the , 5th Edition (DSM-5).
    3. Current diagnosis or history of substance use disorder as defined in the DSM-5. Note: If the history of substance use disorder is more than 12 months before baseline, the participant may be allowed to enroll in the study after consultation with the sponsor or designee. (Participant must also have negative urine drug screen at the screening and Day -2 visit.)
    4. Current active major depressive episode (MDE) or who have had an active MDE in the past 6 months.
  • The participant has a history of cerebral ischemia, (\<5 years ago), intracranial aneurysm, or arteriovenous malformation.
  • The participant had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks before the screening visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo tablets matching TAK-861, orally, twice daily (BID), from Days 1 to 56.

    Drug: Placebo

  • Experimental
    TAK-861 2 milligrams (mg) BID

    Participants received TAK-861 2 mg, orally, BID, from Days 1 to 56.

    Drug: TAK-861 2 mg

  • Experimental
    TAK-861 2 mg and 5 mg

    Participants received TAK-861 2 mg followed by the 5 mg dose, orally, from Days 1 to 56.

    Drug: TAK-861 2 mg and 5 mg

Interventions

  • DrugPlacebo

    TAK-861 placebo matching tablets.

  • TAK-861 2 mg tablets.

  • DrugTAK-861 2 mg and 5 mg

    Drug page: Oveporexton

    TAK-861 2 mg and 5 mg tablets.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8

    The MWT is a validated, objective measure that evaluates a participant's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants were instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session was recorded on EEG. If no sleep was observed according to these rules, then the latency was defined as 40 minutes. The linear mixed effects model for repeated measures (MMRM) was used for analysis.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8

    The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks participants how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. The MMRM was used for analysis.

    Time frame: Baseline, Week 8

  2. Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug.

    Time frame: From first dose of the study drug up to end of the study (up to 3 months)

07

Results

Posted Jan 9, 2025

Participant flow

Participants took part in the study at 28 investigative sites globally from 09 January 2023 to 25 December 2023.

Participant flow — Overall Study
MilestonePlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mg
Started242324
Completed211922
Not completed342
Withdrew: Adverse event120
Withdrew: Withdrawal by subject101
Withdrew: Protocol violation021
Withdrew: Reason not specified100

Outcome measures

PrimaryChange From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8

The MWT is a validated, objective measure that evaluates a participant's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants were instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session was recorded on EEG. If no sleep was observed according to these rules, then the latency was defined as 40 minutes. The linear mixed effects model for repeated measures (MMRM) was used for analysis.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · minutes
Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8
minutesPlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mg
Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 82.14 ± 2.2461.90 ± 2.3844.54 ± 2.300
Statistical analysis
  • Placebo vs TAK-861 2 mg BID · MMRM · p = =0.989 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Ls mean difference estimate: -0.24 · 95% CI -6.67 to 6.18An unstructured variance-covariance structure was used.
  • Placebo vs TAK-861 2 mg and 5 mg · MMRM · p = =0.916 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Ls mean difference estimate: 2.4 · 95% CI -3.93 to 8.72An unstructured variance-covariance structure was used.
SecondaryChange From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8

The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks participants how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. The MMRM was used for analysis.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8
score on a scalePlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mg
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8-3.39 ± 1.140-3.71 ± 1.206-6.45 ± 1.121
Statistical analysis
  • Placebo vs TAK-861 2 mg BID · MMRM · p = =0.989 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Ls mean difference estimate: -0.32 · 95% CI -3.57 to 2.92LS in LS Mean Difference denotes least squares.
  • Placebo vs TAK-861 2 mg and 5 mg · MMRM · p = =0.216 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Ls mean difference estimate: -3.06 · 95% CI -6.18 to 0.06An unstructured variance-covariance structure was used.
SecondaryNumber of Participants With at Least One Treatment Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug.

Time frame:
From first dose of the study drug up to end of the study (up to 3 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
ParticipantsPlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mg
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE)81018

Adverse events

Collected over From first dose of the study drug up to end of the study (up to 3 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/24 (0%)0/24 (0%)2/24 (8.3%)
TAK-861 2 mg BID0/23 (0%)0/23 (0%)7/23 (30.4%)
TAK-861 2 mg and 5 mg0/24 (0%)0/24 (0%)14/24 (58.3%)
Most frequent other events
Most frequent other events
EventPlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mg
PollakiuriaRenal and urinary disorders0/243/238/24
InsomniaPsychiatric disorders2/242/235/24
Pharyngitis streptococcalInfections and infestations0/242/230/24
HeadacheNervous system disorders0/240/232/24
Micturition urgencyRenal and urinary disorders0/241/232/24
Urinary incontinenceRenal and urinary disorders0/240/232/24

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTotal
Mean37.0 ± 12.6934.9 ± 9.7736.8 ± 12.6136.2 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTotal
Female18141749
Male69722
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTotal
Hispanic or Latino65213
Not Hispanic or Latino18182056
Unknown or Not Reported0022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTotal
American Indian or Alaska Native0000
Asian3339
Native Hawaiian or Other Pacific Islander0000
Black or African American71513
White13191446
More than one race0000
Unknown or Not Reported1023
Average Sleep Latency From the Maintenance of Wakefulness Test (MWT)
Average Sleep Latency From the Maintenance of Wakefulness Test (MWT)(minutes)PlaceboTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTotal
Mean10.8 ± 8.729.9 ± 10.298.4 ± 8.269.7 ± 9.04
08

Study locations

56 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213-1966, United States
  • Mayo Clinic Arizona-PPDS
    Scottsdale, Arizona 85259-5452, United States
  • Stanford Center for Sleep Sciences and Medicine
    Redwood City, California 94063, United States
  • SDS Clinical Trials, Inc.
    Santa Ana, California 92705-8519, United States
  • Delta Waves LLC - Hunt - PPDS
    Colorado Springs, Colorado 80918, United States
  • Florida Pediatric Research Institute
    Orlando, Florida 32803-1468, United States
  • Neurotrials Research
    Atlanta, Georgia 30342-1743, United States
  • Georgia Neuro Center
    Gainesville, Georgia 30501-3883, United States
  • Neurocare Inc.
    Newton, Massachusetts 02459, United States
  • Henry Ford Medical Center - Columbus
    Novi, Michigan 48377, United States
  • St. Lukes Sleep Medicine and Research Center
    Chesterfield, Missouri 63017-3406, United States
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
  • ARSM Research, LLC
    Huntersville, North Carolina 28078-5082, United States
  • Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
    Cincinnati, Ohio 45212, United States
  • Intrepid Research
    Cincinnati, Ohio 45227-2172, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio Sleep Medicine Institute
    Dublin, Ohio 43017-3521, United States
  • Medical University of South Carolina - PPDS
    Charleston, South Carolina 29425-5712, United States
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201-2923, United States
  • Comprehensive Sleep Medicine Associates - Sugar Land
    Houston, Texas 77030-2042, United States
  • Sleep Therapy and Research Center
    San Antonio, Texas 78229-4849, United States
  • Children's Specialty Group
    Norfolk, Virginia 23510-1021, United States
  • Woolcock Institute of Medical Research
    Glebe, New South Wales 2037, Australia
  • Terveystalo Helsinki Sleep Clinic
    Helsinki, Uusimaa 00380, Finland
  • Hopital Saint-Eloi
    Montpellier, Herault 34090, France
  • CHU de Grenoble
    La Tronche, Isere 38700, France
  • Hopital de la Pitie Salpetriere
    Paris, 75013, France
  • Somni Bene Institut fur Medizinische Forschung und Schlafmedizin Schwerin GmbH
    Schwerin, Mecklenburg-Vorpommern 19053, Germany
  • Advanced Sleep Research GmbH
    Berlin, 10117, Germany
  • Fondazione PTV Policlinico Tor Vergata
    Roma, Lazio 00133, Italy
  • Istituto Neurologico Mediterraneo Neuromed
    Pozzilli, Molise 86077, Italy
  • IRCCS Istituto delle Scienze Neurologiche di Bologna
    Bellaria, 40139, Italy
  • Akita University Hospital
    Akita-Shi, Akita 010-8543, Japan
  • Ehime University Hospital
    Toon-Shi, Ehime 791-0295, Japan
  • You Ariyoshi Sleep Clinic
    Kitakyushu-city, Hukuoka 806-0021, Japan
  • Kurume University Hospital
    Kurume-Shi, Hukuoka 830-0011, Japan
  • Howakai Kuwamizu Hospital
    Kumamoto-Shi, Kumamoto 862-0954, Japan
  • Gokeikai Osaka Kaisei Hospital
    Osaka-Shi, Osaka 532-0003, Japan
  • Koishikawa Tokyo Hospital
    Bunkyo-Ku, Tokyo 112-0012, Japan
  • National Center of Neurology and Psychiatry
    Kodaira-Shi, Tokyo 187-8551, Japan
  • Yoyogi Sleep Disorder Center
    Shibuya-Ku, Tokyo 151-0053, Japan
  • Aichi Medical University Hospital
    Nagakute, 480-1195, Japan
  • RESM respiratory and sleep medical-care clinic
    Yokohama, 222-0033, Japan
  • Kempenhaeghe - PPDS
    Heeze, Noord-Brabant 5591 VE, Netherlands
  • Slaap-Waakcentrum SEIN Heemstede
    Heemstede, Noord-Holland 2103 SW, Netherlands
  • Oslo Universitetssykehus HF Rikshospitalet
    Oslo, 0450, Norway
  • Hospital Universitario Araba Santiago
    Vitoria-Gasteiz, Alava 1004, Spain
  • Hospital General Universitari de Castello
    Castellón De La Plana, Castellon 12004, Spain
  • Hospital de La Ribera
    Alzira, Valencia 46600, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Instituto de Investigaciones del Sueno
    Madrid, 28036, Spain
  • Hospital Vithas Madrid Arturo Soria
    Madrid, 28043, Spain
  • Sahlgrenska Universitetssjukhuset
    Goteborg, Vastra Gotalands Lan 413 90, Sweden
  • Klinik Barmelweid AG
    Barmelweid, Aargau (de) 5017, Switzerland
  • Neurocenter of Southern Switzerland
    Lugano, Ticino (it) 6900, Switzerland
  • Universitaetsspital Bern - Inselspital
    Bern, 3010, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Dec 2023, 11 months.

Results were first posted in Jan 2025, 1 year after primary completion.

Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Jan 18, 2023
StartActual
Jan 9, 2023
Primary completionActual
Dec 13, 2023
CompletionActual
Dec 25, 2023
Results first posted
Jan 9, 2025
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05687916
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Jan 9, 2023
Primary completion
Dec 13, 2023
Completion
Dec 25, 2023
Results posted
Jan 9, 2025
Last update
Jan 9, 2025

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oveporexton

Start the discussion